HealthTree

Showing 134 trials matching your filters.

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.

DRUG: AVM0703

Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or...

This early phase I clinical trial evaluates bridging radiation therapy given before chimeric antigen receptor (CAR) T-cell infusion to treat large B-cell lymphoma (LBCL) that has come back (relapsed) or has not responded to previous treatment (refrac...

PROCEDURE: Biospecimen Collection

BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy

PROCEDURE: Computed Tomography

RADIATION: External Beam Radiation Therapy

PROCEDURE: Leukapheresis

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (...

The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLY™), either by itself or together with other therapies, when treating subjects with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial...

DRUG: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone

DRUG: rituximab and lenalidomide

DRUG: rituximab and bendamustine

DRUG: rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin

DRUG: gemcitabine and oxaliplatin

BIOLOGICAL: Epcoritamab

DRUG: rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone

DRUG: Lenalidomide

DRUG: rituximab, ifosfamide, carboplatin, and etoposide phosphate

BIOLOGICAL: Epcoritamab

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Unt...

This phase I trial studies the side effects of polatuzumab vedotin when given with combination chemotherapy with or without glofitamab for the treatment of patients with untreated large B-cell lymphoma that grows and spreads quickly and has severe sy...

DRUG: Polatuzumab Vedotin

BIOLOGICAL: Rituximab

DRUG: Prednisone

DRUG: Etoposide

DRUG: Doxorubicin

DRUG: Cyclophosphamide

BIOLOGICAL: Glofitamab

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Echocardiography

PROCEDURE: FDG-Positron Emission Tomography

PROCEDURE: Computed Tomography

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T C...

This phase I trial evaluates the best dose, possible benefits and/or side effects of fludarabine and cyclophosphamide with or without rituximab before CD19 chimeric antigen receptor T cells in treating patients with diffuse large B-cell lymphoma that...

BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

BIOLOGICAL: Rituximab

DALY II USA/ MB-CART2019.1 for DLBCL

DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after rece...

BIOLOGICAL: zamtocabtagene autoleucel (MB-CART2019.1)

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Bendamustine

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin L...

This phase I/II trial finds out the best dose, possible benefits and/or side effects of ALX148 in combination with rituximab and lenalidomide in treating patients with indolent and aggressive B-cell non-Hodgkin lymphoma. Immunotherapy with ALX148, ma...

DRUG: CD47 Antagonist ALX148

DRUG: Lenalidomide

BIOLOGICAL: Rituximab

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults ...

The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). Initial treatment cures 90% - 95% of children with these malignancies, leaving a very small population of relapse...

DRUG: Epcoritamab

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibito...

DRUG: LP-168

Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Ther...

This is an interventional study to evaluate the use of CTO1681 in preventing or reducing CAR T-cell-induced toxicities like cytokine release syndrome (CRS). This study will enroll adult patients with DLBCL who are scheduled to receive CD19-directed C...

DRUG: CTO1681 10 μg

DRUG: CTO1681 20 μg

DRUG: CTO1681 30 μg

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas T...

This phase I trial tests the safety, side effects, and best dose of combination therapy with tazemetostat and belinostat in treating patients with lymphomas that have returned (relapsed) or resisted treatment (refractory). Tazemetostat is in a class ...

DRUG: Belinostat

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

OTHER: Pharmacokinetic Study

PROCEDURE: Positron Emission Tomography and Computed Tomography Scan

DRUG: Tazemetostat

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell N...

This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL). The main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells and to learn more abou...

DRUG: Odronextamab

Study of E7777 Prior to Kymriah for R/R DLBCL

This is a single institution Phase I study to determine the maximum tolerated dose (MTD) of E7777 when given prior to cyclophosphamide/fludarabine (CY/Flu) lymphodepletion (LD) chemotherapy and Kymriah, a commercial tisagenlecleucel product, for the ...

DRUG: E7777

Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients o...

To learn if adding epcoritamab to the treatment combination R-miniCVP (rituximab, cyclophosphamide, vincristine, prednisone) can help to control newly diagnosed DLBCL. The safety of this combination will also be studied.

DRUG: Prednisone

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Vincristine

DRUG: Epcoritamab

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of D...

This phase I/II trial tests the safety of tafasitamab, retifanlimab, and rituximab (TRR) as a prephase treatment and in combination with standard therapy consisting off cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or polatuzumab ...

PROCEDURE: Bone Marrow Biopsy

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Prednisone

BIOLOGICAL: Retifanlimab

BIOLOGICAL: Rituximab and Hyaluronidase Human

BIOLOGICAL: Tafasitamab

DRUG: Vincristine

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Multigated Acquisition Scan

OTHER: Fludeoxyglucose F-18

PROCEDURE: Positron Emission Tomography

PROCEDURE: Computed Tomography

PROCEDURE: Biospecimen Collection

DRUG: Polatuzumab Vedotin

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

Background: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cured have a poor prognosis. Researchers want to add another drug to standard treatment see i...

DRUG: DA-EPOCH

BIOLOGICAL: Rituximab

DRUG: CHOP

DRUG: Acalabrutinib

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Ma...

B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-525 as a monot...

DRUG: ABBV-525

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-...

This phase Ib trial studies the effects of NKTR-255 in combination with chimeric antigen (CAR)-T cell therapy and to see how well they work in treating patients with large B-cell lymphoma that has come back (relapsed) or does not respond to treatment...

DRUG: Cyclophosphamide

DRUG: Fludarabine

BIOLOGICAL: Lisocabtagene Maraleucel

DRUG: Polymer-conjugated IL-15 Receptor Agonist NKTR-255

PROCEDURE: X-Ray Imaging

PROCEDURE: Echocardiography

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Lumbar Puncture

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

PROCEDURE: Biospecimen Collection

PROCEDURE: Biopsy

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblas...

This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.

DRUG: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)

Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma

This phase I/II trial studies the safety of acalabrutinib and axicabtagene ciloleucel in treating patients with B-cell lymphoma. Acalabrutinib may stop the growth of tumor cells by blocking key pathways needed for cell growth. Immunotherapy with axic...

DRUG: Acalabrutinib

BIOLOGICAL: Axicabtagene Ciloleucel

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligi...

This phase II clinical trial evaluates tafasitamab and lenalidomide followed by tafasitamab and the carboplatin, etoposide and ifosfamide (ICE) regimen as salvage therapy for transplant eligible patients with large B-cell lymphoma that has come back ...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

DRUG: Carboplatin

PROCEDURE: Computed Tomography

DRUG: Etoposide

DRUG: Ifosfamide

DRUG: Lenalidomide

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Tafasitamab

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large ...

This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabta...

BIOLOGICAL: Axicabtagene Ciloleucel

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Fludarabine

BIOLOGICAL: Lisocabtagene Maraleucel

BIOLOGICAL: Mosunetuzumab

OTHER: Patient Observation

DRUG: Polatuzumab Vedotin

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Tisagenlecleucel

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies o...

This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies or voruciclib in combi...

DRUG: voruciclib monotherapy

DRUG: voruciclib and venetoclax

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lympho...

This phase Ib/II trial is aimed at studying the combination of a drug named Selinexor (selective inhibitor of nuclear export) in combination with standard therapy for B cell Non-Hodgkin's lymphoma called R-CHOP. The investigators will establish maxim...

DRUG: Selinexor

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insuffi...

This partially randomized clinical trial studies cholecalciferol in improving survival in patients with newly diagnosed cancer with vitamin D insufficiency. Vitamin D replacement may improve tumor response and survival and delay time to treatment in ...

DIETARY_SUPPLEMENT: Cholecalciferol

OTHER: Laboratory Biomarker Analysis

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or refractory cluster of differentiation (CD)19-positive B-cell malignancies.

BIOLOGICAL: CNTY-101

BIOLOGICAL: IL-2

DRUG: Lymphodepleting Chemotherapy

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine a...

This phase I trial tests safety, side effects and best dose of B-cell activating factor receptor (BAFFR)-based chimeric antigen receptor T-cells, with fludarabine and cyclophosphamide lymphodepletion, for the treatment of patients with B-cell hematol...

BIOLOGICAL: Autologous BAFFR-targeting CAR T Cells

DRUG: Bendamustine

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

PROCEDURE: Echocardiography

DRUG: Fludarabine

PROCEDURE: Leukapheresis

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B...

This phase II trial studies the safety and how well of loncastuximab tesirine when given together with mosunetuzumab works in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refract...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

BIOLOGICAL: Loncastuximab Tesirine

BIOLOGICAL: Mosunetuzumab

PROCEDURE: Positron Emission Tomography

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291...

Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-291 in...

DRUG: ABBV-291

Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies

This study is a multi-center study to evaluate the safety of KUR-502 in subjects with refractory/relapsed B-cell NHL or leukemia (ALL or CLL).

GENETIC: KUR-502

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.

DRUG: NX-2127

Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

This phase I trial tests the safety, side effects, and best dose of tegavivint in treating patients with large b-cell lymphomas that has come back (relapsed) or does not respond to treatment (refractory). Tegavivint may stop the growth of cancer cell...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

DRUG: Tegavivint

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatmen...

This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies). Giving chemotherapy and total-body irradiation before a ...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

DRUG: Cyclophosphamide

DRUG: Cyclosporine

BIOLOGICAL: Filgrastim

DRUG: Fludarabine

DRUG: Mycophenolate Mofetil

DRUG: Mycophenolate Sodium

RADIATION: Total-Body Irradiation

DRUG: Treosulfan

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Echocardiography

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants Wi...

The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.

DRUG: Loncastuximab Tesirine

DRUG: Rituximab

DRUG: Gemcitabine

DRUG: Oxaliplatin

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chron...

This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significance and chro...

DIETARY_SUPPLEMENT: Ascorbic Acid

DRUG: Carboplatin

DRUG: Cisplatin

DRUG: Cytarabine

DRUG: Dexamethasone

DRUG: Etoposide

DRUG: Gemcitabine Hydrochloride

DRUG: Ifosfamide

OTHER: Laboratory Biomarker Analysis

DRUG: Oxaliplatin

OTHER: Placebo Administration

OTHER: Questionnaire Administration

BIOLOGICAL: Rituximab

DRUG: Decitabine

PROCEDURE: Biospecimen Collection

PROCEDURE: Core Biopsy

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Echocardiography

PROCEDURE: Positron Emission Tomography

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Central Venous Cannula Insertion

PROCEDURE: Portacath Placement

PROCEDURE: Computed Tomography

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

This phase I trial tests the safety, side effects, and best dose of nivolumab in combination with ASTX727 in treating B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodie...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Decitabine and Cedazuridine

BIOLOGICAL: Nivolumab

PROCEDURE: Positron Emission Tomography

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic...

This phase Ib trial evaluates the side effects and best dose of choline salicylate given together with a low dose of selinexor in treating patients with non-Hodgkin or Hodgkin lymphoma, or multiple myeloma whose prior treatment did not help their can...

DRUG: Choline Salicylate

DRUG: Selinexor

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Ref...

The purpose of this study is to evaluate the safety and preliminary efficacy of ATA3219 in participants with relapsed/refractory (R/R) B-cell non-Hodgkin Lymphoma (NHL).

DRUG: ATA3219

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malign...

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell l...

BIOLOGICAL: Zilovertamab vedotin

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

This is a multicenter Phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 administration following standard of care CD19 CAR T-cell therapy for eligible subjects with r/r LBCL.

DRUG: Efineptakin alfa

DRUG: Tisagenlecleucel

DRUG: Axicabtagene ciloleucel

DRUG: Lisocabtagene Maraleucel

Study Evaluating SC291 in Subjects with R/r B-cell Malignancies (ARDENT)

SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.

DRUG: SC291

Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy

The purpose of the study is to evaluate whether receiving the pneumococcal 13-valent conjugate vaccine (PCV13) before and after CD19-targeted CAR T cell therapy will optimize cellular and humoral immunity to pneumococcus.

BIOLOGICAL: Pneumococcal conjugate vaccine (PCV13)

BIOLOGICAL: CD19 targeted CAR T Cell Therapy

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With ...

This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone \[R-miniCHOP\]) versus R-miniCHOP alon...

PROCEDURE: Biospecimen Collection

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

DRUG: Oral Azacitidine

DRUG: Prednisone

OTHER: Questionnaire Administration

BIOLOGICAL: Rituximab

DRUG: Vincristine Sulfate

IKS03 in Patients with Advanced B Cell Non-Hodgkin Lymphomas

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in...

DRUG: IKS03

Auto Stem Cell Transplant for Lymphoma Patients

This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.

DRUG: Etoposide

DRUG: BCNU

DRUG: AraC

DRUG: Melphalan

PROCEDURE: Peripheral blood stem cell transplantation

BIOLOGICAL: G-CSF

DRUG: Cyclophosphamide

RADIATION: Total Body Irradiation

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to ...

This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Lenalidomide

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

BIOLOGICAL: Tafasitamab

DRUG: Tazemetostat

DRUG: Zanubrutinib

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous (IV) infusion to subjects with advanced solid tumo...

DRUG: RNK05047

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin ...

Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT). If patients achieve either complete, partial, or stable response following ASCT, they will receive an IV dose of Polatuzu...

DRUG: Polatuzumab vedotin

A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B...

DRUG: AZD0486 IV

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma. This research study involves the study drug acalabr...

DRUG: ACALABRUTINIB

DRUG: LISOCABTAGENE MARALEUCEL

DRUG: Lymphodepleting chemotherapy

Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Di...

This early phase I trial investigates how well duvelisib exposure before CAR-T cell manufacturing works to enhance immune profiles of T cells in patients with diffuse large B-cell lymphoma that has come back (recurrent) or does not respond to treatme...

DRUG: Duvelisib

BIOLOGICAL: Tisagenlecleucel

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Dis...

This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative ...

DRUG: Fludarabine

DRUG: Cyclophosphamide

RADIATION: Total Body Irradiation

DRUG: Cyclosporine A

DRUG: Mycophenylate mofetil

BIOLOGICAL: Umbilical cord blood

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large...

This study will evaluate the safety and efficacy of NKTR-255 following CD19-directed chimeric antigen (CAR)-T cell therapy in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). NKTR-255 is an investigational IL-15 receptor agon...

DRUG: NKTR-255 at 1.5 µg/kg

DRUG: NKTR-255 at 3.0 μg/kg

DRUG: NKTR-255 at 3.0/6.0 μg/kg

OTHER: Placebo Comparator

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 that can be given safely to participants * Evaluate the ...

DRUG: AC676

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With ...

The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. T...

BIOLOGICAL: Zilovertamab vedotin

BIOLOGICAL: Rituximab

DRUG: Gemcitabine

DRUG: Oxaliplatin

DRUG: Bendamustine

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematol...

The purpose of the study is to find out if an investigational drug called PRGN-3007 UltraCAR-T cells (PRGN-3007 T cells) can help people with ROR1-positive hematologic chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphoblasti...

DRUG: Fludarabine

DRUG: Cyclophosphamide

BIOLOGICAL: PRGN-3007

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

This is a clinical trial to evaluate the feasibility and safety of giving tazemetostat followed by standard of care CAR T cell infusion in previously treated diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (M...

DRUG: Tazemetostat Pill

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV...

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is the most co...

DRUG: ABBV-319

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

This phase 1 pilot study examines the feasibility and safety of mosunetuzumab after autologous stem cell transplant for patients with aggressive B cell lymphomas. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in ...

DRUG: Mosunetuzumab

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the ...

This phase II trial studies the effect of rituximab, lenalidomide, acalabrutinib, tafasitamab alone and in combination with chemotherapy in treating patients with newly diagnosed non-germinal center diffuse large B-cell lymphoma. Rituximab and tafasi...

DRUG: Acalabrutinib

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

DRUG: Lenalidomide

DRUG: Prednisone

BIOLOGICAL: Rituximab

BIOLOGICAL: Tafasitamab

DRUG: Vincristine

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs:...

DRUG: CD79b-19 CAR T cells

DRUG: Cyclophosphamide

DRUG: Fludarabine

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

This phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab for the treatment of patients who have received chimeric antigen receptor (CAR) T cell therapy for non-Hodgkins lymphoma and in whom have had a sub-optimal res...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Golcadomide

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Rituximab

Study of SGR-1505 in Mature B-Cell Neoplasms

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

DRUG: SGR-1505

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back. Acalabrutinib is a small molecular inhib...

DRUG: Acalabrutinib

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

The purpose of the study is to assess the safety and efficacy of once daily itacitinib oral administration in participants with diffuse large B-cell lymphoma (DLBCL) who will receive CAR-T cell therapy with axicabtagene ciloleucel (axi-cel).

DRUG: Itacitinib

BIOLOGICAL: Chimeric antigen receptor (CAR) T-cell therapy

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR...

Background: Aggressive B-cell lymphomas can be cured but people with disease that resists treatment or that returns after treatment have poor outcomes with standard therapies. Indolent B-cell lymphomas are generally incurable with standard therapy a...

BIOLOGICAL: obinutuzumab

DRUG: prednisone

DRUG: Revlimid

BIOLOGICAL: Polatuzumab

DRUG: ibrutinib

DRUG: venetoclax

TTI-622 in Combination with Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large ...

This phase II trial tests the safety, side effects, and best dose of TTI-621 (closed to enrollment) or TTI-622 in combination with pembrolizumab in treating patients with diffuse large B-cell lymphoma that has come back after a period of improvement ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Ontorpacept

BIOLOGICAL: Pembrolizumab

PROCEDURE: Positron Emission Tomography

DRUG: Maplirpacept

PROCEDURE: Biopsy

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell ...

Background: B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas. The drugs are venet...

DRUG: Venetoclax

DRUG: Ibrutinib

DRUG: Prednisone

BIOLOGICAL: Obinutuzumab

DRUG: Revlimid (lenalidomide)

Study of Oral MRT-2359 in Selected Cancer Patients

This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high-grade neuroendocrine cancer of any primary site, d...

DRUG: Oral MRT-2359

A Safety Study of SGN-35C in Adults With Advanced Cancers

This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma. This study will enroll people who have classical Hodgkin lymphoma (cHL), peripheral T cell lympho...

DRUG: SGN-35C

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient S...

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess th...

DRUG: Epcoritamab

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

This phase I trial tests the safety, side effects, best dose and effectiveness of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS) lymphoma. Lenalidomide may s...

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Echocardiography

DRUG: Lenalidomide

PROCEDURE: Lumbar Puncture

PROCEDURE: Magnetic Resonance Imaging

DRUG: Methotrexate

BIOLOGICAL: Nivolumab

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Rituximab

PROCEDURE: Ultrasound Imaging

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Pl...

The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymp...

DRUG: Relatlimab

DRUG: Nivolumab

A Safety Study of SGN-35T in Adults With Advanced Cancers

This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infections. There are several types of lymphoma. This study will enroll people who have lymphoma, such as classical Hodgkin lymphoma, peripheral ...

DRUG: SGN-35T

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells with Chimeric...

The study is designed to examine the feasibility and safety of collecting autologous hematopoietic stem cells (HSCs) to be combined with CAR T-cell therapy for patients with relapsed/refractory (r/r) hematological disease. The study will evaluate fea...

BIOLOGICAL: autologous hematopoietic stem cells added to planned CAR T

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

This phase II trial studies how well polatuzumab vedotin and combination chemotherapy work in treating patients with previously untreated double, triple hit lymphoma, Double Expressor Lymphoma or High-Grade B Cell Lymphoma. Polatuzumab vedotin is a m...

DRUG: Prednisone

DRUG: Prednisolone

DRUG: Methylprednisolone

BIOLOGICAL: Rituximab

DRUG: Polatuzumab Vedotin

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy. This research is being do...

RADIATION: Adaptive Bridging Radiation Therapy (ABRT)

Zanubrutinib in Combination with R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Ly...

This phase Ib trial seeks to find out the best dose and possible side effects and/or benefits of zanubrutinib in combination with the R-PolaCHP in treating patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Zanubrutinib is designed ...

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Vincristine Sulfate

DRUG: Zanubrutinib

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

This phase II trial tests how well zanubrutinib and lisocabtagene maraleucel (liso-cel) work together in treating patients with Richter's syndrome. Richter's syndrome occurs when chronic lymphocytic leukemia and/or small lymphocytic leukemia transfor...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Fludarabine

PROCEDURE: Leukapheresis

BIOLOGICAL: Lisocabtagene Maraleucel

PROCEDURE: Lymph Node Biopsy

PROCEDURE: Positron Emission Tomography

DRUG: Zanubrutinib

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

This phase II trial tests whether loncastuximab tesirine works to shrink tumors in patients with B-cell malignancies that have come back (relapsed) or does not respond to treatment (refractory). Loncastuximab tesirine is a monoclonal antibody, called...

BIOLOGICAL: Loncastuximab Tesirine

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects ...

This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.

DRUG: DPX-Survivac

DRUG: Pembrolizumab

DRUG: CPA

Iomab-ACT: a Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patie...

This is a pilot study; patients will receive 131-I apamistamab prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab is exceeded at 75 mCi, and if so, to assess the safety of a step-down dose of 50 mCi.

DRUG: 131-I Apamistamab

BIOLOGICAL: CAR T-cell

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

DRUG: BGB-16673

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas. The main goals of this study are to: * Find t...

DRUG: IMT-009

COMBINATION_PRODUCT: Fruquintinib

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chem...

Subjects with relapsed large cell lymphoma will receive 3 cycles of combination therapy consisting of GDP and epcoritamab. Each cycle will last 21 days. GDP consists of gemcitabine 1000 mg/m2 IV on Days 1 and 8, cisplatin 75 mg/m2 IV on Day 1, and de...

PROCEDURE: AutoSCT OR CAR T-cell Therapy

DRUG: GDP

DRUG: Epcoritamab

CAR-T Followed by Bispecific Antibodies

The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who ...

DRUG: mosunetuzumab

DRUG: glofitamab

DRUG: obinutuzumab

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard fron...

DRUG: Acalabrutinib

BIOLOGICAL: Rituximab

Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Dif...

This phase II trial evaluates whether loncastuximab tesirine and rituximab followed by dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone works to treat patients with high risk diffuse large B-cell lymphoma. Loncastux...

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Etoposide

BIOLOGICAL: Loncastuximab Tesirine

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Vincristine

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Eps...

A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas

DRUG: Nanatinostat in combination with valganciclovir

Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma

The goal of this clinical trial is to learn about treatment for people with B-cell lymphoma that did not respond to treatment or that has gotten worse after treatment. The aim of this trial is to answer the following questions: * If it is realistic ...

RADIATION: Bridging radiation therapy

BIOLOGICAL: Liso-cel

RADIATION: Post-infusion radiation

Study of IMPT-314 in R/R Aggressive B-cell NHL

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive B-cell NHL. Three co...

DRUG: IMPT-314

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenou...

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gem...

DRUG: Epcoritamab

DRUG: Rituximab

DRUG: Lenalidomide

DRUG: Oxaliplatin

DRUG: Gemcitabine

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.

DRUG: NX-5948

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-ce...

The goal of this research study is to evaluate the combination of study drugs, Glofitamab and Polatuzumab, and a standard chemotherapy regimen, R-CHP, as a treatment for high-risk diffuse large B-cell lymphoma. The names of the treatment interventio...

DRUG: Glofitamab

DRUG: Polatuzumab

DRUG: Rituximab

DRUG: Doxorubicin Hydrochloride

DRUG: Cyclophosphamide

DRUG: Prednisone

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NP...

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.

DRUG: BMF-219

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Follow...

This phase I trial studies the safety and side effects of cytomegalovirus (CMV) specific CD19-chimeric antigen receptor (CAR) T-cells along with the CMV-modified vaccinia Ankara (MVA) triplex vaccine following a stem cell transplant in treating patie...

BIOLOGICAL: Anti-CD19-CAR CMV-specific T-lymphocytes

PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation

BIOLOGICAL: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

PROCEDURE: Myeloablative Conditioning

A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab...

The purpose of this study is to learn about the effects of two study medicines (maplirpacept \[PF-07901801\] and glofitamab) when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that is relapsed or is refractory. Relapsed me...

DRUG: maplirpacept (PF-07901801)

DRUG: Glofitamab

DRUG: Obinutuzumab

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants...

This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate t...

DRUG: PRT2527

DRUG: Zanubrutinib

DRUG: Venetoclax

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.

DRUG: Epcoritamab

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin ...

This phase I trial studies the side effect and best dose of ibrutinib in combination with rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride in treating patients with human immunodeficiency virus (H...

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

DRUG: Etoposide

BIOLOGICAL: Filgrastim

DRUG: Ibrutinib

OTHER: Laboratory Biomarker Analysis

BIOLOGICAL: Pegfilgrastim

OTHER: Pharmacological Study

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Vincristine Sulfate

Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transp...

This is a two-arm, open-label, phase Ib single-site study with expansion cohorts testing the addition of mosunetuzumab to intensive platinum-based salvage chemotherapy in patients with relapsed/refractory aggressive B cell lymphoma intending to pursu...

DRUG: Mosunetuzumab

DRUG: DHAX

DRUG: ICE

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through th...

Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of ABBV-101 in adult partici...

DRUG: ABBV-101

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leu...

BIOLOGICAL: Rapcabtagene autoleucel single agent

DRUG: Ibrutinib

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide fo...

This phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin and lenalidomide in treating patients with diffuse large B-cell lymphoma (DLBCL) that has come back after a period of improvement ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Lenalidomide

BIOLOGICAL: Mosunetuzumab

DRUG: Polatuzumab Vedotin

PROCEDURE: Positron Emission Tomography

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients with Recurrent or Refractory B-Ce...

This phase I trial studies the side effects and best dose of CD19/CD20 chimeric antigen receptor (CAR) T-cells when given together with chemotherapy, and to see how effective they are in treating patients with non-Hodgkin's B-cell lymphoma or chronic...

BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

BIOLOGICAL: Tocilizumab

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ H...

This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.

DRUG: SYNCAR-001

DRUG: STK-009

DRUG: Cyclophosphamide

DRUG: Fludarabine

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

In this research study is looking to see how safe and effective belantamab mafodotin is in relapsed or refractory plasmablastic lymphoma or ALK+ large B-cell lymphoma. * This research study involves the study drug belantamab mafodotin. * Belantamab ...

DRUG: Belantamab Mafodotin

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Di...

The overarching goals of this study are to measure levels of circulating tumor DNA (ctDNA) in patients with early stage diffuse large B cell lymphoma (DLBCL), to assess the change in ctDNA during treatment in order to prospectively identify markers o...

DRUG: Rituximab Prednisone

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cem...

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy ...

DRUG: ONM-501

DRUG: Cemiplimab

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies

BIOLOGICAL: P-CD19CD20-ALLO1

DRUG: Rimiducid

Study Evaluating SC262 in Subjects with R/r Non-Hodgkin's Lymphoma (VIVID)

SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.

DRUG: SC262

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patient...

The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric antigen rece...

DRUG: Selinexor (combination therapy)

DRUG: Placebo matching for Selinexor (combination therapy)

DRUG: Rituximab (combination therapy)

DRUG: Gemcitabine (combination therapy)

DRUG: Dexamethasone (combination therapy)

DRUG: Cisplatin (combination therapy)

DRUG: Selinexor (continuous therapy)

DRUG: Placebo matching for Selinexor (continuous therapy)

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission ...

This phase II trial compares epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in complete remission after treatment with CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. Epc...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

BIOLOGICAL: Epcoritamab

PROCEDURE: Magnetic Resonance Imaging

OTHER: Patient Observation

PROCEDURE: Positron Emission Tomography

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

This research study is evaluating the combination of drugs, pembrolizumab with chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment for primary mediastinal B-cell lymphoma that has recurred after prior treatment. The names of the ...

DRUG: Pembrolizumab

DRUG: Lymphodepletion Chemotherapy

DRUG: Chimeric Antigen Receptor (CAR) Therapy Infusion

PROCEDURE: Leukapheresis

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against...

This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with diffuse large B-cell lymphoma (DLBCL) that have not been treated before (...

DRUG: Odronextamab

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone/Prednisolone

SynKIR-310 for Relapsed/Refractory B-NHL

This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

BIOLOGICAL: SynKIR-310

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by...

BIOLOGICAL: HSCT with TBI Regimen

BIOLOGICAL: HSCT with Non-TBI Regimen

A Study of NX-1607 in Adults With Advanced Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

DRUG: NX-1607

DRUG: Paclitaxel

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feas...

BIOLOGICAL: 8/12-Day Production of Car-T Cells

BIOLOGICAL: 8/12-Day Production of Cryopreserved Car-T Cells

BIOLOGICAL: 12-Day Production of Car-T Cells

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

The goal of this clinical trial is to learn about how a combination of tazemetostat and venetoclax in people with relapsed/refractory Non-Hodgkin Lymphoma (R/R NHL). The main questions that this trial aims to answer are what is the best dose of venet...

DRUG: Venetoclax

DRUG: Tazemetostat

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab i...

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic ...

DRUG: Epcoritamab

DRUG: Lenalidomide

DRUG: Ibrutinib

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride [HCl]

DRUG: Prednisone

DRUG: Polatuzumab Vedotin

DRUG: Venetoclax

DRUG: CC-99282

DRUG: Pirtobrutinib

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

This study aimed to evaluate the efficacy of a novel regimen consisting of polatuzumab vedotin in combination with rituximab, gemcitabine, dexamethasone, and cisplatin (PV-RGDP) for the treatment of diffuse large B-cell lymphoma that either came back...

DRUG: Polatuzumab vedotin (PV)

DRUG: Rituximab

DRUG: Hyaluronidase

DRUG: Gemcitabine

DRUG: Cisplatin

DRUG: Dexamethasone

DRUG: GCSF

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relaps...

This is an open label, non-randomized, phase 1 study of anti-CD19 CAR-T cells against relapsed CD19 positive NHL, CLL and ALL based in a lymphodepletion regimen (fludarabine and cyclophosphamide) and using a CellReGen-based process for manufacturing ...

BIOLOGICAL: Anti-CD19 CAR-T cells

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for childre...

DRUG: Obinutuzumab

DRUG: Liposomal ARA-C

DRUG: Ifosfamide

DRUG: Carboplatin

DRUG: Etoposide

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethaso...

BACKGROUND: * Primary CNS lymphoma (PCNSL) is a rare subtype of diffuse large B-cell lymphoma. * The outcome for patients with this diagnosis is significantly worse than for that of systemic DLBCL. Most treatment approaches in the past have included...

DRUG: Isavuconazole

DRUG: TEDDI

BIOLOGICAL: Rituximab

DRUG: Cytarabine

DRUG: TEDD

DRUG: Ibrutinib (Arms 2, 3 and 4)

DRUG: Methotrexate

DRUG: Ibrutinib (Arm 1 - Closed with Amendment G)

DRUG: Ibrutinib (Arm 4)

A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

A Phase 1/2 Study of bbT369, a dual targeting CAR T cell drug product with a gene edit, in Relapsed and/or Refractory B cell Non-Hodgkin's Lymphoma.

BIOLOGICAL: bbT369

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymp...

This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19)

DRUG: Fludarabine

DRUG: Cyclophosphamide

BIOLOGICAL: anti-CD19 CAR-T cells

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

This is a randomized, open-label study in adult patients who have completed standard first line of therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual d...

GENETIC: cemacabtagene ansegedleucel

BIOLOGICAL: ALLO-647

DRUG: Fludarabine

DRUG: Cyclophosphamide

DEVICE: Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™

A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of firicabtagene autoleucel (firi-cel), a CD22-directed autologous Chimeric...

DRUG: Fludarabine (Conditional therapy)

DRUG: Cyclophosphamide Monohydrate (Conditional therapy)

DRUG: firi-cel (Experimental drug)

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (rel...

BIOLOGICAL: Axicabtagene Ciloleucel

DRUG: Cyclophosphamide

DRUG: Fludarabine

A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2.

DRUG: CPI-0209

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Pos...

This phase Ib/II clinical trial tests the safety, side effects, and effectiveness of mosunetuzumab with chemotherapy for the treatment of patients with untreated, c-Myc rearrangement positive, high grade B cell lymphoma or diffuse large B cell lympho...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Doxorubicin

PROCEDURE: Echocardiography

DRUG: Etoposide

PROCEDURE: Magnetic Resonance Imaging

BIOLOGICAL: Mosunetuzumab

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Positron Emission Tomography

DRUG: Prednisone

DRUG: Vincristine

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intrav...

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intravenous a...

DRUG: Epcoritamab

DRUG: Cyclophosphamide

DRUG: Rituximab

DRUG: Vincristine

DRUG: Doxorubicin

DRUG: Prednisone

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refra...

This phase I trial tests the safety, side effects, and best dose of genetically engineered cells called EGFRt/19-28z/IL-12 CAR T cells, and to see how they work in treating patients with hematologic malignancies that makes a protein called CD19 (CD19...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

PROCEDURE: Echocardiography

BIOLOGICAL: EGFRt/19-28z/IL-12 CAR T-lymphocytes

DRUG: Fludarabine Phosphate

PROCEDURE: Leukapheresis

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Positron Emission Tomography

Thanks to our HealthTree Community for Hepatosplenic T-Cell Lymphoma Sponsors:

Need Help?

Legal Info

Charity Navigator

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Tax ID 45-5354811

Get the latest thought leadership on your Hepatosplenic T-Cell Lymphoma delivered straight to your inbox

Thanks to our HealthTree Community for Hepatosplenic T-Cell Lymphoma Sponsors:

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info